Specimen Collection Manual and Test Catalog

FFPE tissue: Six (6) unstained slides (USS), 10 µm thickness each, in slide folder (protected from light)
Bone Marrow: 3 mL lavender-top K2 EDTA tube (part of Bone Marrow Panel Collection – Bone Marrow Aspirate – Two [2] K2 EDTA Tube[s])
Fresh tissue: Place in liquid medium (e.g., RPMI)

FFPE tissue: For non-Geisinger sites, send six (6) unstained slides, 10 µm thickness, H&E slide, source of specimen and tumor assessment. Alternatively, send the FFPE block and additional information.
Bone marrow: For non-Geisinger sites, collection tube is included in the bone marrow (BM) collection kit.
NOTE: Isolated/extracted nucleic acids are acceptable only from CLIA-certified laboratories or a laboratory meeting equivalent requirements as determined by CAP and/or CMS.

Mix well immediately. Do not centrifuge or separate plasma from cells.

FFPE tissue:  Room temperature (18-25°C).
Bone marrow/fresh tissue: Refrigerated (2-8°C)

FFPE Tissue: Room temperature (18-25°C), indefinitely
Bone marrow/fresh tissue: Refrigerated (2-8°C), 3 days. Specimen must be extracted within 3 days.

FFPE blocks containing no tumor (evaluated by pathologist). FFPE tissues that have been decalcified. Insufficient DNA and/or RNA. Wrong collection tube. Improper storage or transport temperature. Stability limits exceeded. Shared or comingled specimens.

Negative (no mutations detected)

This assay is based on the next-generation sequencing (NGS) of RNA (cDNA) and is a multigene panel which detects somatic oncogenic gene fusions and exon skipping. Genes included in the assay are ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, ARID1A, ATF1, AXL, BCOR, BCORL1, BRAF, BRD3, BRD4, CAMTA1, CCNB3, CCND1, CD274, CIC, CREB3L1, CREB3L2, CRTC1, CRTC3, CSF1, CSF1R, CTNNB1, DDIT3, DDX3X, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLI1, FLT1, FLT3, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GNA14, GNAQ, GRB7, GRM1, HMGA2, HRAS, IDH1, IDH2, IGF1R, INSR, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6, MERTK, MET, MGEA5, MKL2, MN1, MSMB, MUSK, MYB, MYBL1, MYC, MYH9, MYOD1, NCOA1, NCOA2, NCOA3, NCOA4, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NOTCH3, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, NUTM2A, PATZ1, PAX3, PAX5, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PGR, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRB3, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, PTCH1, PTPN1, RAD51B, RAF1, RELA, RET, RLF, ROS1, RSPO2, RSPO3, SERPINE1, SMAD3, SMARCA2, SMARCA4, SRF, SS18, SS18L1, STAT6, TAF15, TCF12, TEK, TERT, TFE3, TFEB, TFG, TGFA, TGFBR3, THADA, TMPRSS2, USP6, VGLL2, VGLL3, WWTR1, YAP1, YWHAE.

Next Generation Sequencing
RNA extraction

Next Generation Sequencing, RNA Fusion, Sarcoma, Solid Tumor Gene Panel, FUSGP

The MyGenVar Pan Fusion Gene Panel targets RNA fusions and exon skipping by high-throughput sequencing. It helps determine diagnostic classification and provide prognostic or therapeutic information for clinical management.

Yi Ding MD, PhD